Relevant Companies
DMD Registry
The DMD Registry is an international database for health professionals and researchers to help accelerate the development and delivery of new treatments for Duchenne and Becker Muscular Dystrophy. The DMD Registry is a secure, legally protected and has been endorsed by senior clinicians, health professionals and researchers.
|
|
Santhera
Santhera Pharmaceuticals AG is a Swiss biopharmaceutical company founded in 2004 through a merger between Germany-based Graffinity Pharmaceuticals AG and Swiss-based MyoContract AG. Santhera is focused on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of neuromuscular diseases and has a fully integrated platform for the discovery and development of drug candidates. The company, headquartered in Switzerland, has operations in Liestal, Switzerland (near Basel) and in Heidelberg, Germany, as well as a business development office in Boston, MA, USA. Santhera's investors comprise Merlin Biosciences Limited, Oxford Bioscience Partners, NGN Capital, 3i Group plc, Carnegie Asset Management, The Novartis Venture Fund, Varuma AG, GIMV, Clariden Bank, The Dow Chemical Company, Heidelberg Innovation, TechnoStart, tbg, the Swiss Foundation for Research on Muscle Diseases, and private investors.
|
|
CosySoles
The only slippers that heat the entire surface of your feet with long-lasting warmth while providing the freedom to walk about comfortably!
|
|
CepTor
Ceptor Corporation is a development-stage biopharmaceutical company focusing on therapeutic products for neuromuscular and neurodegenerative diseases. Our mission is to increase the quality and quantity of life of the people who suffer from these diseases. We are striving to accomplish this mission through a proprietary, receptor mediated drug-targeting platform and, to a large extent, the inhibition of the protease calpain, as well as the specific delivery of other therapeutic compounds. Ceptor is preparing to file an investigational new drug application (IND) and move its lead product, MYODUR, into phase I/II clinical trials for muscular dystrophy. We are also currently developing products for multiple sclerosis and epilepsy. The Company’s platform technology will provide several orphan drug candidates for efficient, internal development, according to our business model, as well as larger patient market product opportunities appropriate for corporate partnering.
|
|
PTC Therapeutics
PTC Therapeutics, Inc. (PTC) is a biopharmaceutical company focused on the discovery and commercialization of orally active small molecule therapeutics for human diseases.
|
|
Actions
Category Stats
Listings: 5
Regular: 5
Last listing added: 07/19/05
Details
Rate
Report
Comments (0)